{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041137","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.624075+00:00","generated_at":"2026-06-08T03:56:28.191562+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Anebulo Q1 FY2024 net loss $2.5M; FDA positive on Phase 3 path for ANEB-001","bullets":["Net loss of $2.5M ($0.10/sh) vs $2.6M ($0.11/sh) in prior year quarter; operating expenses $2.5M.","Cash $8.5M as of Sep 30; secured credit facility of up to $10M from existing investors.","FDA Type B meeting: single ED study plus larger THC challenge may suffice for NDA for ANEB-001.","Richie Cunningham appointed CEO and Board member; Bimal Shah joined Board; Phase 3 targeted H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041137","json":"https://secwatch.observer/filing/0001493152-23-041137.json","markdown":"https://secwatch.observer/filing/0001493152-23-041137.md","text":"https://secwatch.observer/filing/0001493152-23-041137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223041137/0001493152-23-041137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223041137/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:56:28.191562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76d7ee6e28f82560689ce78e1b3fda7160fe6793","claim":"Anebulo Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: net income $2.5 million, or $(0.10) per share, EPS $(0.10) per share.","evidence_excerpt":"Net loss in the first quarter of fiscal 2024 was $2.5 million, or $(0.10) per share, compared with a net loss of $2.6 million, or $(0.11) per share, in the first quarter of fiscal 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223041137/0001493152-23-041137-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2023"},{"label":"Net income","value":"$2.5 million, or $(0.10) per share"},{"label":"EPS","value":"$(0.10) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}